Effect of nucleotide substitutions in N-acetyltransferase-1 on N-acetylation (deactivation) and O-acetylation (activation) of arylamine carcinogens: Implications for cancer predisposition

Cancer Detection and Prevention

Volumn 26, Issue 1, 2002, Pages 10-14

  Fretland, Adrian J ^a   Doll, Mark A ^a   Zhu, Yuanqi ^a   Smith, Leo ^a   Leff, Matthew A ^a   Hein, David W ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Acetylation polymorphism; N acetyltransferase 1; Recombinant expression; Single nucleotide polymorphism

Indexed keywords

ACETYLATION; ACETYLTRANSFERASES; ALLELES; AMINOBIPHENYL COMPOUNDS; ARYLAMINE N-ACETYLTRANSFERASE; CARCINOGENS; DISEASE SUSCEPTIBILITY; FLUORENES; GENOTYPE; HUMANS; ISOENZYMES; MUTAGENS; MUTATION; PHENOTYPE; POLYMORPHISM, GENETIC; SCHIZOSACCHAROMYCES; VARIATION (GENETICS);

EID: 0036952798     PISSN: 0361090X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-090X(02)00005-3     Document Type: Article

References (28)

1. Miller EC, Miller JA. Search for the ultimate chemical carcinogens and their reaction with cellular macromolecules. Cancer 1981;47:2327-45.
2. Hein DW. Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta 1988;948:37-66.
3. Hein DW, Doll MA, Rustan TD, et al. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 1993;14:1633-8.
4. Hein DW, Doll MA, Fretland AJ, et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidem Biomark Prev 2000;9:29-42.
5. Fretland AJ, Leff MA, Doll MA, et al. Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms. Pharmacogenetics 2001;11:207-15.
6. Blum M, Demierre A, Grant DM, et al. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA 1991;88:5237-41.
7. Deguchi T. Sequences and expression of alleles of polymorphic arylamine N-acetyltransferase of human liver. J Biol Chem 1992;267:18140-7.
8. Hein DW, Ferguson RJ, Doll MA, et al. Molecular genetics of human polymorphic N-acetyltransferase: enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric NAT2 allozymes. Hum Mol Genet 1994;3:729-34.
9. 341/803) and wild-type human polymorphic N-acetyltransferase-2 (NAT2) alleles. Drug Metab Dispos 1994;22:371-6.
10. Hein DW, Rustan TD, Ferguson RJ, et al. Metabolic activation of aromatic and heterocyclic N-hydroxylamines by wild-type and mutant recombinant human NAT1 and NAT2 acetyltransferases. Arch Toxicol 1994;68:129-33.
11. Hein DW, Doll MA, Rustan TD, et al. Metabolic activation of N-hydroxyamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of seven specific NAT2 nucleic acid substitutions. Cancer Res 1995;55:3531-6.
12. Hickman D, Palamanda JR, Unadkat JD, et al. Enzyme kinetic properties of human recombinant arylamine N-acetyltransferase 2 allotypic variants expressed in Escherichia coli. Biochem Pharmacol 1996;50:697-703.
13. Leff MA, Fretland AJ, Doll MA, et al. Novel human N-acetyltransferase 2 alleles that differ in mechanism for slow acetylator phenotype. J Biol Chem 1999;274:34519-22.
14. Fretland AJ, Doll MA, Leff MA, et al. Functional characterization of nucleotide polymorphisms in the coding region of human N-acetyltransferase 1. Pharmacogenetics 2001;11:511-20.
15. Leff MA, Epstein PN, Doll MA, et al. Prostate-specific human N-acetyltransferase 2 (NAT2) expression in the mouse. J Pharmacol Exp Ther 1999;290:182-7.
16. Bruhn C, Brockmoller J, Cascorbi I, et al. Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1. Biochem Pharmacol 1999;58:1759-64.
17. Yang M, Katoh T, Delongchamp R, et al. Relationship between NAT1 genotype and phenotype in a Japanese population. Pharmacogenetics 2000;10:225-32.
18. Butcher NJ, Ilett KF, Minchin RF. Functional polymorphism of the human arylamine N-acetyttransferase type 1 gene caused by C190T and G560A mutations. Pharmacogenetics 1998;8:67-72.
19. Hughes NC, Janezic SA, McQueen KL, et al. Identification and characterization of variant alleles of human NAT1 with defective function using p-aminosalicylate as an in vitro and in vivo probe. Pharmacogenetics 1998;8:55-66.
20. Lin HJ, Probst-Hensch NM, Hughes NC, et al. Variants of N-acetyltransferase-1 NAT1 and case-control study of colorectal adenomas. Pharmacogenetics 1998;8:269-81.
21. Payton MA, Sim E. Genotyping human arylamine N-acetyltransferase type 1 (NAT1): identification of two novel allelic variants. Biochem Pharmacol 1998;55:361-6.
22. Doll MA, Jiang W, Deitz AC, et al. Identification of a novel allele at the human NAT1 acetyltransferase locus. Biochem Biophys Res Commun 1997;233:584-9.
23. de Leon JH, Vatsis KP, Weber WW. Characterization of naturally occurring and recombinant human N-acetyltransferase variants encoded by NAT1*. Mol Pharmacol 2000;58:288-99.
24. Badawi AF, Hirvonen A, Bell DA. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res 1995;55:5230-7.
25. Bell DA, Badawi AF, Lang NP, et al. Polymorphism in the N-acetyltransferase I (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res 1995;55:5226-9.
26. Zenser TV, Lakshmi VM, Rustan TD, et al. Human N-acetylation of benzidine: role of NAT1 and NAT2. Cancer Res 1996;56:3941-7.
27. Hein DW, McQueen CA, Grant DM. Pharmacogenetics of the arylamine N-acetyltransferases: a Symposium in Honor of Wendeu W. Weber. Drug Metab Dispos 2000;28:1425-1432.
28. Butcher NJ, Ilett KF, Minchin RF. Substrate-dependent regulation of human arylamine N-acetyltransferase-1 in cultured cells. Mol Pharmacol 2000;57:468-73.